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Abstract
Background and Purpose
Although bevacizumab (BV) has been approved as second-line therapy for recurrent glioblas-
toma (GB), the efficacy and safety of BV for patients with newly diagnosed GB remain unclear.
Methodology/Principal Findings
We systematically searched electronic databases (PubMed, EMBASE, OVID, etc.) to iden-
tify related studies published from January 1966 and August 2016. Eight randomized con-
trolled trials including a total of 2,185 patients with GB were included. We found that the
median progression-free survival (PFS) was higher in the BV group than in the standard
therapy (ST) group (pooled hazard ratio, 0.73; 95%CI, 0.62–0.86; P = 0.0001). Compared
with ST, BV improved the PFS rate at 6 months (OR 3.33, 95% CI 2.73–4.06, p<0.00001)
and 12 months (OR 2.10, 95% CI 1.74–2.54, p<0.00001). There were no significant differ-
ences in median overall survival between the BV and ST groups (OR, 1.01; 95%CI, 0.83–
1.23; P = 0.95). The BV group had higher survival rates at 6 months (OR, 1.41; 95% CI,
1.09–1.84; P = 0.01) and 12 months (OR, 1.23; 95% CI, 1.02–1.48; P = 0.03), but a low sur-
vival rate at the 36-month follow-up (OR, 0.57; 95% CI, 0.32–0.98; P = 0.04). For the inci-
dence of adverse events, three adverse outcomes were found to be significantly different
between BV and ST groups, including hypertension (8.37% vs. 1.62%, p<0.000001), pro-
teinuria (7.65% vs. 0%, p<0.001), and fatigue (14.54% vs. 9.01%, p = 0.05).
Conclusions/Significance
Our study indicates that combination of BV with ST for newly diagnosed GB did not improve
the median overall survival but result in longer median PFS, maintaining the quality of life
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and functional status. However, the long-term use of BV is associated with a higher inci-
dence of adverse events and mortality.
Study Registration
This research was registered at PROSPERO. (Registration Number: CRD42016038247).
Introduction
Glioblastoma (GB), the most common primary malignant brain tumor in adults, has a dis-
mal prognosis, with a median survival of 14 to 16 months [1]. Even with the best available
standard therapies (surgical resection followed by radiotherapy and temozolomide), the
prognosis of patients with GB remains low [2,3]. When GB recurs, the median overall sur-
vival is typically 3 to 9 months, and available therapies have a limited impact on outcome [4].
Therefore, development of new therapies is essential to improve the overall survival and
prognosis of patients with newly diagnosed GB. During the past decade, a large number of
targeted therapeutic agents have been developed and evaluated. GB is highly vascular and
typically overexpresses vascular endothelial growth factor (VEGF), which promotes tumor
angiogenesis, contributing to tumor growth and progression [5–7]. Several clinical trials
have suggested that VEGF could be a therapeutic target [8,9]. The U.S. Food and Drug
Administration (FDA) approved bevacizumab (BV), a humanized monoclonal antibody to
VEGF, for second-line treatment of recurrent GB [10,11]. Despite its prolongation of pro-
gression-free survival (PFS) in patients with recurrent GB, the impact of BV on overall sur-
vival remains undefined.
Several clinical trials have reported that treatment with combinations of BV and other
chemotherapeutic agents results in stable responses and a prolonged 6-month PFS rate in
patients with recurrent high-grade glioma, but do not significantly prolong overall survival
(OS), compared with previous trials [12–16]. Furthermore, most of the complications caused
by the toxicity of the combined chemotherapy led to discontinuation of treatment for
patients with GB [17]. In 2009, Zhang et al. conducted a meta-analysis to assess the efficacy
and safety of BV alone compared with BV and irinotecan for recurrent GB [18]. The results
indicated that the combination of BV and irinotecan may increase the rate of discontinua-
tion and that there was no obvious improvement in overall survival in patients with recur-
rent GB. Furthermore, this research included only nonrandomized control trials or small-
sample retrospective studies. The data from low-quality research results in significant
heterogeneity.
From 2009 onward, several randomized controlled trials (RCTs) were conducted to assess
the effectiveness of BV for newly diagnosed GB [19–26]. Therefore, it became necessary to
conduct a meta-analysis to assess the clinical efficacy of BV compared with standard therapy
(ST) or other chemotherapies for newly diagnosed GB and to evaluate the safety and adverse
effects of these combinations.
Materials and Methods
There is no necessary for ethic approval in this meta-analysis, which mainly based on the pub-
lished studies. This study was conducted according to the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA) statement [27].
Anti-Angiogenesis Therapy for GB
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Literature Search and Study Selection
Two reviewers (GY.L and MZ.H) performed the literature searching on the BV for patients
with newly diagnosed GB to identify relevant articles published between January 1966 and
August 2016. Electronic search used “bevacizumab”, “avastin”, “chemotherapy”, “glioblas-
toma”, “newly diagnosed glioblastoma”, “GB” in Mesh and free terms. We searched PubMed,
EMBASE, and the Cochrane Library to identify relevant studies. Manual searches were per-
formed to relevant journal and reference lists of retrieved articles. Two independent reviewers
(YP.L and MZ.H) assessed the literature based on the titles and abstracts to identify potentially
relevant articles. Full versions of all relevant articles were obtained and inspected.
Inclusion Criteria and Exclusion Criteria
The inclusion criteria were used for selecting the potential studies: (1) RCTs compare the stan-
dard treatment with or without BV for patients with newly diagnosed GB; (2) the patients
were adults; (3) the main clinical outcomes and complications were reported; and (4) at least 6
months follow-up.
The exclusion criteria of studies were: (1) review; (2) lack of randomization; (3) data could
not be extracted; (4) insufficient clinical data; (5) duplicate papers.
Data Extraction and Qualitative Assessment
The relevant data from selected studies were independently extracted by 2 reviewers (GY.L
and YP.L) as follows: (1) Publishing time, (2) mean age, number of patient, (3) study quality,
(4) Follow up, (5) main results, including overall survival (OS) and progression-free survival
(PFS), and (6) secondary outcomes, adverse events incidence. Two observers assessed method-
ological quality of the included studies. The GRADE approach was introduced to evaluate the
overall methodological quality of including studies as recommended by Cochrane Handbook
for Systematic Review of Interventions [28].
Statistical Methods
Meta-analysis was performed with RevMan software (version 5.1; The Cochrane Collabora-
tion, The Nordic Cochrane Centre, Copenhagen, Denmark). The hazard ratio (HR) with 95%
confidence intervals (CIs) was used to assess main outcomes of the studies, including median
OS, median PFS. HRs and their corresponding SEs were directly extracted from studies. If the
study did not report a HR but gave the data in the form of the survival curve, survival rates at
certain specified times were extracted from them for the reconstruction of the HR estimate
and its SEs. The odds ratio (OR) with 95% confidence intervals (CIs) was used to assess the
rate of OS and PFS at different follow-ups (6, 12, 24, and 36 months). Statistical significance
was accepted as p value less than 0.05. In order, Cochrane Q text (α = 0.05) was performed to
analyze the heterogeneity. If the result of the test of the heterogeneity was P> 0.05, the fixed-
effect model was used. If the result of heterogeneity test was P < 0.05, then the pooled ORs
were analyzed using the random effects model. Publication bias was evaluated with Egger’s
regression test in which P value less than 0.10 were considered representative of statistically
significant publication bias.
Results
Description of the Studies
Fig 1 is a flowchart describing the study selection and inclusion process. The primary search
yielded 2,172 potentially relevant articles (Fig 1). Of these, 2161 were excluded after reading
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titles and abstracts. Two independent reviewers (Y.P.L and H.Z.Z) then reviewed the full texts
of the remaining 12 articles. Four more studies were excluded. Finally, we identified 8 RCTs
including a total of 2,185 patients with newly diagnosed GB (Table 1) [19–26]. Sample size ran-
ged from 54 to 921. Six studies were published in English [19–24] and two in Chinese [25,26].
These articles were published between 2011 and 2015. Details of the treatment and functional
outcome measures are summarized in Table 1.
Fig 1. The PRISMA flow chart of the meta-analysis.
doi:10.1371/journal.pone.0168264.g001
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The Median PFS and PFS Rate
Five studies presented the data of median PFS comparing BV with ST group [19,20,22–24].
Since the significant difference was observed in heterogeneity test (I2 = 52, P = 0.08), the
Table 1. Characteristics of included studies.
Study Inclusion criteria Age (y) Cases (n/M) Treatment Outcome Side-
effect
Follow-up
(m)Experiment Control Experiment Control Experiment Control
Albert Lai
2011
age > 18 years 57.4 59.4 70/39 110/70 BE RT OS Y 42
newly diagnosed
GB
RT TMZ PFS
KPS >60 TMZ Toxicity&Safety
MR. Gilbert
2014
age > 18 years - - 312 309 BE RT OS Y 30
newly diagnosed
GB
RT TMZ PFS
KPS>70 TMZ Toxicity&Safety
MGMT status
OL. Chinot
2014
age > 18 years 57 56 458 463 BE RT OS Y 32
newly diagnosed
GB
RT TMZ PFS
TMZ KPS
supratentorial GHS
B. Chauffert
2014
ages from 18 and
70 y
60.2 60.9 60/34 60/37 BE RT OS Y 24
KPS>50 RT TMZ PFS
histologically
confirmed
TMZ OS
IRI
U Herrlinger
2013
newly diagnosed
GB
56 56 116/80 54/34 BE RT OS 36
KPS>70 RT TMZ PFS
age > 18 years TMZ QoL
IRI
JA. Carlson
2015
age > 18 years 55.9 59.5 30/17 26/16 hypo-IMRT hypo-
IMRT
OS Y 60
newly diagnosed
GB
BE TMZ PFS
KPS>60 TMZ
KF. Hofland
2014
age > 18 years 62 59 32/21 31/18 BE IRI Response Rate Y 31
newly diagnosed
GB
RT RT OS
TMZ TMZ PFS
Jiaqi Wang
2013
newly diagnosed
GB
53.6 54.7 27/16 27/14 BE RT RECIST Y 24
KPS>60 RT TMZ OS
TMZ
GB: Glioblastoma; KPS: Karnofsky performance status; RT: radiotherapy; TMZ: temozolomide; BV: bevacizumab; OS: overall survival; PFS: progression-
free survival; GHS: GlobalHealthStatus; GoL:quality of life; Y: yes;
doi:10.1371/journal.pone.0168264.t001
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random-effects model was applied to analyze data. The pooled HR was 0.73 (95%CI, 0.62–
0.86; P = 0.0001), as shown in Fig 2.
Eight studies reported the PFS rate at different follow-ups comparing BV with ST group
[19–26]. No statistically significant heterogeneity was observed between studies, I2 = 3% at 6
months, 0% at 12 months, and 23% at 24 months; so the fixed effect model was applied. The
pooled OR of PFS was 3.33 at 6 months (95%CI, 2.73–4.06; P<0.00001), 2.10 at 12 months
(95%CI, 1.74–2.54; P<0.00001), 0.85 at 24 months (95%CI, 0.53–1.36; P = 0.48), and 0.53at 36
months follow-ups (95%CI, 0.21–1.34; P = 0.18). (Fig 3)
The Median OS and Survival Rate
Five studies presented the data of median OS [19,20,22–24]. The heterogeneity test showed sig-
nificant differences in each study (I2 = 66, P = 0.02). Then we applied the random-effects
model to analysis the data. The pooled HR of median OS was 1.01 (95%CI, 0.83–1.23;
P = 0.95) as shown in Fig 4.
All included studies [19–26] reported the data of survival rate in different follow-up end
points. The test of total heterogeneity showed no significant differences (I2 = 21, P = 0.18). The
fixed-effects model was applied. The pooled OR of survival rate was 1.41 (95% CI, 1.09–1.84;
P = 0.01) at 6 month, 1.23 (95% CI, 1.02–1.48; P = 0.03) at 12 month, 1.09 (95% CI, 0.89–1.35;
P = 0.40) at 24 month. Moreover, we noted that low survival rate in BV group at 36 month,
and the OR was 0.57 (95% CI, 0.32–0.98; P = 0.04). (Fig 5)
Safety of BV for Patients with Newly Diagnosed GB
Of included trials, five trials provided data of AEs incidence [19,20,22–24]. From these events,
three adverse outcomes were found to be significantly different between bevacizumab and
standard treatment groups, including hypertension (8.37% vs. 1.62%, p<0.000001), protein-
uria (7.65% vs. 0%, p<0.001), fatigue (14.54% vs. 9.01%, p = 0.05), as shown in Table 2. The
incidence of all severe AEs also showed significant between BV and ST group, as showed in
Fig 6. There was significant trend toward with regard to BV therapy and high severe AEs inci-
dence (P = 0.033).
Qualitative Assessment and Publication Bias
The quality of the studies included in this meta-analysis is shown in Table 1. It can be seen
from the funnel plot that the publication bias was low to moderate regarding PFS and OS (Figs
7 and 8).
Fig 2. The pooled HR of median PFS comparing BV with ST in patients with GB.
doi:10.1371/journal.pone.0168264.g002
Anti-Angiogenesis Therapy for GB
PLOS ONE | DOI:10.1371/journal.pone.0168264 December 22, 2016 6 / 16
Discussion
GB is an aggressive malignant brain tumor with a poor prognosis. Despite the use of some
anti-angiogenesis treatments, there remains no successful therapy [1,2]. The average survival
Fig 3. The pooled analysis of PFS rate comparing BV with ST in patients with GB at different follow-ups.
doi:10.1371/journal.pone.0168264.g003
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time is only 14 months after diagnosis [3]. A major clinical problem is the extent to which the
glioma cells invade adjacent brain tissue, making complete surgical removal impossible [29].
Some research has indicated that GB has multistep tumorigenesis ability to activate the vascu-
larization of brain tissue to form new blood vessels, which contribute to tumor growth and
proliferation [29,30]. VEGF has shown promise as a therapeutic target in the treatment of
brain tumors [31]. Bevacizumab was developed to directly inhibit VEGF-associated angiogenic
effects by blocking activation of the VEGF receptor (VEGF-R) [32,33]. Recently, BV was used
as second-line therapy for recurrent GB in some clinical trials [34–37]. To date, no meta-analy-
sis has investigated the effects of BV on the prognosis of newly diagnosed GB.
The principal findings of our meta-analysis can be summarized as follows: (1) BV com-
bined with standard treatments could improve the median PFS of patients with newly diag-
nosed GB and the PFS rate in short-term follow-up (6 and 12 months). (2) There is no
significant difference in median overall survival between patients treated with BV and those
treated with ST; however, more survivors were observed in the BV group in early follow-up
(<12), with this trend reversing at 36 months. (3) The incidence of severe adverse effects was
higher after BV therapy than after ST.
Our results indicate that BV could prolong the median PFS of patients with newly diag-
nosed GB as compared with a ST group. More patients had attained PFS in the BV group than
in the ST group at 6 months (78.26% vs. 53.19%) and 12 months (41.26% vs. 27.34%) follow-
up; at the 2-year follow-up, we found the PFS rates of the BV and ST groups were equivalent.
Furthermore, one study reported a decreased PFS rate in the BV group compared with the ST
group at 3 years. On the basis of the aforementioned evidence, we conclude that BV improves
the short-term PFS rate (<12 months). These results are consistent with previous clinical trials.
The AVAglio trial reported median PFS durations of 10.6 months in the BV group and 6.2
months in the ST group [23], and the RTOG 0825 trial obtained the same results for PFS dura-
tion (10.7 months in the BV group vs. 7.3 months in the ST group) [22]. However, these two
large RCTs did not report PFS rates at 3 years of follow-up. The decreased PFS was observed
after long-term application of BV (>3 years), which might be caused by BV resistance, chronic
comorbid conditions, or side effects. Additional clinical trials are needed to clarify this issue.
Our study indicated that BV did not improve the median overall survival of patients with
newly diagnosed GB. This finding coincides with those of the AVAglio, RTOG 082512, and
GLARIUS trials, indicating approximately equivalent overall survival (OS) for the BV and ST
groups (11.1% vs. 11.7%, p = 0.59) [22–24]. However, comparison of OS rates at different fol-
low-up points revealed more survivors in the BV group early in follow-up (<12 months), with
this trend reversing at 36 months. Our data indicate that with prolonged use of BV, patients
with GB exhibited worse neurocognition and higher mortality, compared with controls.
Fig 4. The pooled HR of median OS comparing BV with ST in patients with GB.
doi:10.1371/journal.pone.0168264.g004
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Fig 5. The pooled analysis of OS rate comparing BV with ST in patients with GB at different follow-ups.
doi:10.1371/journal.pone.0168264.g005
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Until now, our knowledge of the mechanism underlying the pro-tumor effect of long-term
BV treatment has been limited. One clinical study reported that nearly half of patients with GB
treated with BV had a low response rate [38]. The rebound of tumor invasion and metastasis
was observed by radiography [39]. Several experiments in animals have found more perivascu-
lar invasion, more peritumoral satellite lesions, and higher expression of invasion-related pro-
teins with long-term BV treatment as compared with short-term BV treatment [40,41]. Lucio
Eterovic et al. found that with increasing concentration of BV administered, U87 glioma cells
secreted greater amounts of matrix metalloproteinase (MMP)-2, MMP-9, and MMP-12, and
activated other angiogenic pathways, promoting the migration and invasion of tumor cells
[40]. More importantly, in this research, BV was combined with MMP inhibitor (GM6001) in
Table 2. The adverse events of patients with newly diagnosed GB between BV and ST groups.
Adverse Event n (studies) BV group ST group OR P
n(III-IV) n(total) n(III-IV) n(total)
Cerebral ischemia 2 7 127 1 56 3.21 [0.39, 26.71] 0.28
Cerebral Hemorrhage 4 9 848 7 750 2.30 [0.96, 5.54] 0.06
Diarrhea 3 5 154 0 83 6.14 [0.34, 112.49] 0.22
Neutropenia 3 31 344 19 316 1.55 [0.86, 2.80] 0.15
Nausea and vomit 2 11 287 5 260 2.03 [0.70, 5.93] 0.19
Fatigue 2 48 330 21 233 1.72 [1.00, 2.96] 0.05
Hypertension 4 71 848 12 739 5.54 [2.98, 10.29] <0.000001
Infection 3 16 154 4 83 2.29 [0.74, 7.09] 0.15
Proteinuria 2 33 431 0 560 94.24 [5.76, 1542.53] <0.001
Thromboembolic event 4 56 805 55 766 0.97 [0.66, 1.42] 0.86
Anemia 3 9 344 7 317 1.19 [0.44, 3.23] 0.73
doi:10.1371/journal.pone.0168264.t002
Fig 6. The incidence of all severe AEs in patients with newly diagnosed GB.
doi:10.1371/journal.pone.0168264.g006
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the glioma mouse model. The results indicated that those therapies could prolong survival
and suppress tumor progression [40]. Recently, results from animal research suggested that
minocycline reduces glioma growth by inducing glioma autophagy [42]. In addition, an
ongoing clinical trial found that use of radiation, followed by BV and minocycline, to treat
recurrent GB may improve the effect of long-term BV treatment. (ClinicalTrials.gov Identifier:
NCT01580969)
Drug resistance was considered another factor influencing the effectiveness of BV treatment
for GB. BV was able to inhibit the VEGF—VEGFR signal pathway to suppress tumor growth
[43]. Although this could reduce cerebral oxygen delivery, which up regulates the expression
of HIF-10, it will result in a rebound in the expression of VEGF genes [44,45]. In addition, a
multidirectional cytokine, placental growth factor (PlGF), which is homologous to VEGF, can
promote the proliferation and migration of endothelial cells. When VEGF is inhibited, endo-
thelial cells upregulate the expression of PlGF to maintain tumor-associated vascular growth
[46]. Recently, several researchers found that some cytokines overexpressed in glioma cells
after BV treatment contribute to angiogenesis, including platelet-derived growth factor, fibro-
blast growth factor, interleukin-8 and -10, and angiopoietin-1 [47–49].
Fig 7. The funnel plot of PFS on patients with newly diagnosed GB.
doi:10.1371/journal.pone.0168264.g007
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The adverse events of BV might affect the quality of life and prognosis of patients with GB.
The most common adverse events of BV included abdominal pain, headache, fatigue, hyper-
tension, diarrhea, neutropenia, wound infections, cerebral hemorrhage or ischemia, nausea
and vomiting, thromboembolism, and anemia. To assess the incidence of severe adverse effects
(AEs) in BV treatment of adults newly diagnosed with GB, we extracted all BV-associated
severe AEs from the five studies included in this meta-analysis. We found that those treated
with BV had an increased symptom burden and incidence of severe AEs. In a previous meta-
analysis assessing the risk of adverse vascular events in patients newly diagnosed with GB, BV
therapy was not found to significantly influence the risk of all-cause discontinuation, thrombo-
cytopenia, deep vein thrombosis, and pulmonary embolism in adult patients newly diagnosed
with GB [50]. The authors, however, did report a trend toward significance with respect to BV
therapy and the risk of pulmonary embolism [50]. Therefore, in patients under treatment with
BV, care should be taken to monitor blood pressure, blood clotting function, kidney function,
and other indicators.
Fig 8. The funnel plot of OS on patients with newly diagnosed GB.
doi:10.1371/journal.pone.0168264.g008
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Limitation
The present study has several limitations. First, because only eight RCTs were included, small
sample size and highly selected patient populations could generate selective bias. Second,
there were insufficient data on mutation status and BV resistance. Third, most of the studies
included studies reported the OS and PFS rates only within 2 years of follow-up. Considering
the long-term survival rate, further studies reporting OS rates at 3 years or longer follow-ups
are needed to clarify this issue. Fourth, although all the included studies used ST combined
with BV for newly diagnosed GB, two studies administered BV combined with irinotecan and
one study combined BV with hypofractionated intensity modulated radiation therapy in the
experimental groups, which may have caused heterogeneity in comparisons. Fifth, new thera-
pies are continuing to show the potential benefits for patients with newly diagnosed GB, such
as carmustine wafer (CW). A meta-analysis from Chowdhary SA et al. indicated that CW
treatment could significantly improve the overall several and survival rate of patients with
newly diagnosed or recurrent high-grade GB [51]. Therefore, further studies are required to
investigate the effect of BV combined with other therapies for newly diagnosed GB, such as
CW. Sixth, relevant factors could influence the prognosis of patients with newly diagnosed
GB, including patient age, gender, obesity, steroid use, and smoking history. Because such
individual data were lacking, this study did not assess these factors.
Conclusions
In summary, our study indicates that BV therapy does not appear to improve median OS in
patients with newly diagnosed GB, whereas it prolongs median PFS. We also found that BV
therapy improves the PFS and OS rates at the 6- and 12-months follow-ups. However, at 36
months, the decreased OS rate and high incidence of severe AEs in those treated with BV
make quality of life an issue.
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